16 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
1 Recruiting S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate
2 Recruiting Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
3 Recruiting Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
Conditions: Leukemia;   Lymphoma
Intervention: Other: biologic sample preservation procedure
4 Recruiting Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Other: biologic sample preservation procedure
5 Recruiting Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Conditions: Lymphoma;   Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure;   Other: informational intervention
6 Recruiting Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
7 Recruiting Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: pentostatin
8 Recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Conditions: Lymphoma;   Neurotoxicity;   Therapy-related Toxicity
Interventions: Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
9 Recruiting Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
10 Recruiting Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Condition: Lymphoma
Intervention: Biological: ofatumumab
11 Recruiting Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
Conditions: Breast Cancer;   Lymphedema;   Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention;   Other: educational intervention;   Procedure: assessment of therapy complications;   Procedure: complementary or alternative medicine procedure;   Procedure: management of therapy complications;   Procedure: quality-of-life assessment;   Procedure: therapeutic conventional surgery
12 Unknown  Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Xcellerated T Cells
13 Recruiting Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Conditions: Solid Tumors;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Glioblastoma Multiforme;   Oligodendroglioma;   Hepatocellular Carcinoma;   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: CC-122 HCL
14 Recruiting Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
15 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
16 Recruiting Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: methotrexate;   Drug: pegaspargase;   Drug: cyclophosphamide;   Drug: mercaptopurine;   Biological: blinatumomab;   Drug: etoposide;   Drug: prednisone;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years